Vyome Holdings, Inc. (HIND)vsRoyalty Pharma Plc (RPRX)
HIND
Vyome Holdings, Inc.
$2.25
+1.35%
HEALTHCARE · Cap: $15.09M
RPRX
Royalty Pharma Plc
$56.43
-2.64%
HEALTHCARE · Cap: $32.78B
Smart Verdict
WallStSmart Research — data-driven comparison
Royalty Pharma Plc generates 1597937% more annual revenue ($2.44B vs $152,720). RPRX leads profitability with a 33.9% profit margin vs 0.0%. RPRX earns a higher WallStSmart Score of 65/100 (C+).
HIND
Avoid18
out of 100
Grade: F
RPRX
Buy65
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for HIND.
Margin of Safety
-64.1%
Fair Value
$34.68
Current Price
$56.43
$21.75 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Conservative balance sheet, low leverage
Reasonable price relative to book value
Keeps 34 of every $100 in revenue as profit
Strong operational efficiency at 100.3%
Earnings expanding 23.2% YoY
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Weak financial health signals
Expensive relative to growth rate
Moderate valuation
Elevated debt levels
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : HIND
The strongest argument for HIND centers on Debt/Equity, Price/Book.
Bull Case : RPRX
The strongest argument for RPRX centers on Profit Margin, Operating Margin, EPS Growth. Profitability is solid with margins at 33.9% and operating margin at 100.3%. Revenue growth of 11.0% demonstrates continued momentum.
Bear Case : HIND
The primary concerns for HIND are EPS Growth, Market Cap, Profit Margin.
Bear Case : RPRX
The primary concerns for RPRX are PEG Ratio, P/E Ratio, Debt/Equity.
Key Dynamics to Monitor
HIND profiles as a value stock while RPRX is a mature play — different risk/reward profiles.
RPRX is growing revenue faster at 11.0% — sustainability is the question.
RPRX generates stronger free cash flow (761M), providing more financial flexibility.
Monitor BIOTECHNOLOGY industry trends, competitive dynamics, and regulatory changes.
Bottom Line
RPRX scores higher overall (65/100 vs 18/100), backed by strong 33.9% margins and 11.0% revenue growth. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Vyome Holdings, Inc.
HEALTHCARE · BIOTECHNOLOGY · USA
Vyome Holdings Inc., a clinical-stage healthcare company, develops therapeutic products targeting immuno-inflammatory and rare diseases in the United States and global markets. The company is headquartered in Princeton, New Jersey.
Royalty Pharma Plc
HEALTHCARE · BIOTECHNOLOGY · USA
Royalty Pharma plc is a buyer of biopharmaceutical royalties and funder of innovations in the biopharmaceutical industry in the United States. The company is headquartered in New York, New York.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?